Trial To Assess Efficacy Of A Chimeric Skin In Patients With Epidermolysys Bullosa
NCT ID: NCT00987142
Last Updated: 2019-08-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
12 participants
INTERVENTIONAL
2006-12-31
2010-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients
NCT05725018
A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing
NCT01749306
Clinic Trial in Phase 1 Using Amniotic Membrane for the Skin Replacement in Big Wounds
NCT01948934
Grafting of Epidermolysis Bullosa Wounds Using Cultured Revertant Autologous Keratinocytes
NCT01454687
Oleogel-S10 in Wound Healing of Inherited Epidermolysis Bullosa (BEB-10)
NCT01294241
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Immediately after the surgical procedure, a patch of cultured chimeric skin (experimental therapy) will be implanted in a half of the skin defect of the patient, and an occlusive non - adherent dressing (control) will be implanted in the other half.
Patients will initially be followed up every two days until epithelisation occurs (approximately 21 days after surgery) and at 3,8,and 12 months of follow-up.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CX501
Cultured chimeric skin
CX501
Cultured chimeric skin
Non adherent dressing
Occlusive non adherent dressing
Occlusive non adherent dressing
Application of an occlusive non adherent dressing in the skin donor site
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CX501
Cultured chimeric skin
Occlusive non adherent dressing
Application of an occlusive non adherent dressing in the skin donor site
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with recessive dystrophic epidermolysis bullosa diagnosed by clinical and historical criteria with severe skin syndactyly in whom reconstructive surgery is indicated.
* Patients whose legal guardians have given written informed consent for participation in the study before any study procedure is performed.
* Patients aged ≥ 12 years who have given written informed consent for participation in the study before any study procedure is performed.
Exclusion Criteria
* Pregnant or nursing women
* Documented or suspected hypersensitivity to any of the therapeutic agents included in the study, including anaesthetic drugs.
* Patients with a history of malignant tumor in the past 5 years
* Patients with a diagnosis of active tuberculosis at the time of recruitment
* Patients with prior positive markers for any of the following pathogens: hepatitis b and c, hiv-1 and hiv-2
* Patients with a history of clinically relevant hepatic, gastrointestinal, haematological, pulmonary, or neurological disease no directly related to epidermolysis bullosa.
* Any other medical condition which, in the investigator´s judgment, might interfere with optimal participation in the study or involve a significant risk for the patient.
* Alcoholism, drug addiction, psychiatric disorders, or other factors present in legal guardians which,in the investigator´s judgment may complicate patient participation in the study.
28 Days
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tigenix S.A.U.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Juan Carlos López, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital La Paz
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fundación Mir-Mir
Barcelona, , Spain
Hospital La Paz
Madrid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CX501/TCEB
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.